| Pedro Lucero, MD | |
|
1 Jarrett White Rd, Dept Of Med Mchk-dmp/tamc1 Jarrett White Rd, Tamc, HI 96859-5001 | |
| (808) 433-6792 | |
| Not Available |
| Full Name | Pedro Lucero |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 27 Years |
| Location | 1 Jarrett White Rd, Tamc, Hawaii |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1942291950 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | Q0309 (Texas) | Secondary |
| 207RP1001X | Internal Medicine - Pulmonary Disease | Q0309 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercy Health Hackley Campus | Muskegon, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mercy Health Partners Sub-specialty Services | 3274504105 | 30 |
News Archive
Amgen today announced that new data from a pivotal Phase 2 study evaluating BLINCYTO (blinatumomab) for the treatment of adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL) was presented at the 56th American Society of Hematology Annual Meeting and Exposition.
Pain is the most common symptom leading patients to see a physician in the United States, yet the most widely prescribed medications - opioids and non-steroidal anti-inflammatory drugs (NSAIDS) - have major drawbacks, including the potential for misuse and abuse and adverse effects that limit long-term use. While scientists have made great strides in understanding the physical and chemical processes that occur when people feel pain, new treatments with improved safety and effectiveness are still needed for the more than 76 million Americans with acute and chronic pain.
BD (Becton, Dickinson and Company) has voluntarily executed a product recall of certain lots of BD Q-Syte™ Luer Access Devices and BD Nexiva™ Closed IV Catheter Systems. Use of the affected devices may cause an air embolism or leakage of blood and/or therapy, which may result in serious injury or death. This field corrective action included notification to customers worldwide by letter. Neither the costs anticipated with the recall, nor the impact on BD's business, are expected to be material.
The U.S. government Thursday released a six-year strategy to address malaria globally, Reuters reports (Fox, 4/22). The plan was issued through the President's Malaria Initiative (PMI) in conjunction with World Malaria Day, April 25, and is a "core component of President [Barack] Obama's Global Health Initiative," according to a USAID press release (4/22).
› Verified 8 days ago
| Entity Name | Mclaren Northern Michigan |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760736094 PECOS PAC ID: 9931018181 Enrollment ID: O20040415001193 |
News Archive
Amgen today announced that new data from a pivotal Phase 2 study evaluating BLINCYTO (blinatumomab) for the treatment of adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL) was presented at the 56th American Society of Hematology Annual Meeting and Exposition.
Pain is the most common symptom leading patients to see a physician in the United States, yet the most widely prescribed medications - opioids and non-steroidal anti-inflammatory drugs (NSAIDS) - have major drawbacks, including the potential for misuse and abuse and adverse effects that limit long-term use. While scientists have made great strides in understanding the physical and chemical processes that occur when people feel pain, new treatments with improved safety and effectiveness are still needed for the more than 76 million Americans with acute and chronic pain.
BD (Becton, Dickinson and Company) has voluntarily executed a product recall of certain lots of BD Q-Syte™ Luer Access Devices and BD Nexiva™ Closed IV Catheter Systems. Use of the affected devices may cause an air embolism or leakage of blood and/or therapy, which may result in serious injury or death. This field corrective action included notification to customers worldwide by letter. Neither the costs anticipated with the recall, nor the impact on BD's business, are expected to be material.
The U.S. government Thursday released a six-year strategy to address malaria globally, Reuters reports (Fox, 4/22). The plan was issued through the President's Malaria Initiative (PMI) in conjunction with World Malaria Day, April 25, and is a "core component of President [Barack] Obama's Global Health Initiative," according to a USAID press release (4/22).
› Verified 8 days ago
| Entity Name | Mercy Health Partners Sub-specialty Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124042700 PECOS PAC ID: 3274504105 Enrollment ID: O20040804000803 |
News Archive
Amgen today announced that new data from a pivotal Phase 2 study evaluating BLINCYTO (blinatumomab) for the treatment of adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL) was presented at the 56th American Society of Hematology Annual Meeting and Exposition.
Pain is the most common symptom leading patients to see a physician in the United States, yet the most widely prescribed medications - opioids and non-steroidal anti-inflammatory drugs (NSAIDS) - have major drawbacks, including the potential for misuse and abuse and adverse effects that limit long-term use. While scientists have made great strides in understanding the physical and chemical processes that occur when people feel pain, new treatments with improved safety and effectiveness are still needed for the more than 76 million Americans with acute and chronic pain.
BD (Becton, Dickinson and Company) has voluntarily executed a product recall of certain lots of BD Q-Syte™ Luer Access Devices and BD Nexiva™ Closed IV Catheter Systems. Use of the affected devices may cause an air embolism or leakage of blood and/or therapy, which may result in serious injury or death. This field corrective action included notification to customers worldwide by letter. Neither the costs anticipated with the recall, nor the impact on BD's business, are expected to be material.
The U.S. government Thursday released a six-year strategy to address malaria globally, Reuters reports (Fox, 4/22). The plan was issued through the President's Malaria Initiative (PMI) in conjunction with World Malaria Day, April 25, and is a "core component of President [Barack] Obama's Global Health Initiative," according to a USAID press release (4/22).
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Pedro Lucero, MD Dept Of Med Mchk-dmp/tamc, 1 Jarrett White Rd, Tripler Army Medical Center, HI 96859 Ph: (808) 433-6792 | Pedro Lucero, MD 1 Jarrett White Rd, Dept Of Med Mchk-dmp/tamc1 Jarrett White Rd, Tamc, HI 96859-5001 Ph: (808) 433-6792 |
News Archive
Amgen today announced that new data from a pivotal Phase 2 study evaluating BLINCYTO (blinatumomab) for the treatment of adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL) was presented at the 56th American Society of Hematology Annual Meeting and Exposition.
Pain is the most common symptom leading patients to see a physician in the United States, yet the most widely prescribed medications - opioids and non-steroidal anti-inflammatory drugs (NSAIDS) - have major drawbacks, including the potential for misuse and abuse and adverse effects that limit long-term use. While scientists have made great strides in understanding the physical and chemical processes that occur when people feel pain, new treatments with improved safety and effectiveness are still needed for the more than 76 million Americans with acute and chronic pain.
BD (Becton, Dickinson and Company) has voluntarily executed a product recall of certain lots of BD Q-Syte™ Luer Access Devices and BD Nexiva™ Closed IV Catheter Systems. Use of the affected devices may cause an air embolism or leakage of blood and/or therapy, which may result in serious injury or death. This field corrective action included notification to customers worldwide by letter. Neither the costs anticipated with the recall, nor the impact on BD's business, are expected to be material.
The U.S. government Thursday released a six-year strategy to address malaria globally, Reuters reports (Fox, 4/22). The plan was issued through the President's Malaria Initiative (PMI) in conjunction with World Malaria Day, April 25, and is a "core component of President [Barack] Obama's Global Health Initiative," according to a USAID press release (4/22).
› Verified 8 days ago
Dr. George Heard Underwood Jr., M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 1 Jarrett White Rd, Mchk-im, Tripler Army Medical Center, Tamc, HI 96859 Phone: 808-433-3585 Fax: 808-433-2870 | |
Dr. Jeffrey L Berenberg, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 1 Jarrett White Rd, Mchk-dmo, Tamc, Tamc, HI 96859 Phone: 808-433-4089 Fax: 808-433-2707 | |
Dr. Christy Taoka, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 1 Jarrett White Rd, Tamc, HI 96859 Phone: 808-433-6641 Fax: 808-433-1555 | |
Dr. Charlene Schambach Mcwilliams, D.O. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1 Jarrett White Rd, Dept Of Internal Medicine, Tamc, HI 96859 Phone: 808-433-5720 | |
Eleanor Ruth Hastings, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1 Jarrett White Rd, Tripler Army Medical Center, Tamc, HI 96859 Phone: 808-433-2478 | |
Dr. Clarissa Tana Burkert, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1 Jarrett White Rd, Tripler Army Medical Center Attn: Mchk-qs, Tamc, HI 96859 Phone: 808-433-2460 Fax: 808-433-1558 | |
Dr. Joseph Sergio Gomes Pina, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 1 Jarrett White Rd, Tripler Army Medical Center, Tamc, HI 96859 Phone: 808-433-5720 Fax: 808-433-1555 |